ParisaSalehiMD

Pediatric Endocrinology • Anchorage, AK

Associate Professor, Pediatrics, U of WA Sch of Med

Join to view full profile

Dr. Salehi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salehi's full profile

Already have an account?

Office
4320 Diplomacy Dr
Anchorage, AK 99508
Phone+1 907-729-3300

Fax+1 907-729-5180

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Endocrinology, 2010 - 2013
Children's Hospital of Orange CountyResidency, Pediatrics, 2007 - 2010
University of Nevada, Reno School of MedicineClass of 2007

Certifications & Licensure

CA State Medical License 2009 - Present
AK State Medical License 2024 - 2026
WA State Medical License 2013 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Endocrinology

Clinical Trials

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome Start of enrollment: 2012 Mar 01
Completed
Not Applicable
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Start of enrollment: 2014 Sep 01
Terminated
Phase 3

Publications & Presentations

PubMed

12 citations
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Jennifer L Miller, Evelien Gevers, Nicola Bridges, Jack A Yanovski, Parisa Salehi
The Journal of Clinical Endocrinology and Metabolism. 2023-06-16
47 citations
A multidisciplinary approach to the clinical management of Prader-Willi syndrome.
Jessica Duis, Pieter Joost van Wattum, Ann O. Scheimann, Parisa Salehi, Elly Brokamp
Molecular Genetics & Genomic Medicine. 2019-01-29
7 citations
Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature.
Robert C. Olney, Parisa Salehi, Timothy C. R. Prickett, John J. Lima, Eric A. Espiner
Clinical Endocrinology. 2016-10-01